Abstract
234.0±46.9‰). The serum MDA level in the STZ group was significantly elevated, which was not reversed by addition of rebamipide. The expression of gastric HO-1 in the STZ group was significantly increased, and this increase was supressed by rebamipide supplementation. The expression of gastric c-kit was not affected by the administration of rebamipide. Conclusion. Administration of rebamipide improved diabetic gastric motility disorders through protection against HO-1 reactive gastric oxidative stress.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call